BCAL Diagnostics Ltd (ASX: BDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
BCAL Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$31.34 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
368.68 million
Earnings per share
-0.020
Dividend per share
N/A
Year To Date Return
-19.05%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
BCAL Diagnostics Ltd (ASX: BDX)
Latest News
Healthcare Shares
'Breakthrough results': Why this ASX healthcare share just exploded 160%
Healthcare Shares
3 ASX health care shares that outpaced the market on Friday
BDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About BCAL Diagnostics Ltd
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. It also associated lipids, biomarker blood test that is used for prevention, screening and monitoring. The company was founded by Jayne Shaw and Ron Philips in 2010 and is headquartered in Sydney, Australia.
BDX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Apr 2026 | $0.09 | $0.00 | 0.00% | 57,585 | $0.09 | $0.09 | $0.08 |
| 23 Apr 2026 | $0.09 | $0.00 | 0.00% | 35,536 | $0.09 | $0.09 | $0.09 |
| 22 Apr 2026 | $0.09 | $0.00 | 0.00% | 116,210 | $0.09 | $0.09 | $0.09 |
| 21 Apr 2026 | $0.09 | $0.00 | 0.00% | 6,526 | $0.09 | $0.09 | $0.09 |
| 20 Apr 2026 | $0.09 | $0.00 | 0.00% | 323,038 | $0.09 | $0.09 | $0.09 |
| 17 Apr 2026 | $0.09 | $0.00 | 0.00% | 25,000 | $0.09 | $0.09 | $0.09 |
| 16 Apr 2026 | $0.09 | $0.00 | 0.00% | 34,090 | $0.09 | $0.09 | $0.09 |
| 15 Apr 2026 | $0.09 | $0.00 | 0.00% | 420,934 | $0.09 | $0.09 | $0.08 |
| 14 Apr 2026 | $0.09 | $-0.01 | -10.87% | 166,532 | $0.09 | $0.09 | $0.09 |
| 13 Apr 2026 | $0.09 | $0.00 | 0.00% | 5,543 | $0.09 | $0.09 | $0.09 |
| 10 Apr 2026 | $0.09 | $0.00 | 0.00% | 50,045 | $0.09 | $0.09 | $0.09 |
| 08 Apr 2026 | $0.09 | $0.00 | 0.00% | 130,177 | $0.09 | $0.09 | $0.09 |
| 07 Apr 2026 | $0.09 | $-0.01 | -10.10% | 655 | $0.09 | $0.09 | $0.09 |
| 02 Apr 2026 | $0.10 | $0.01 | 10.87% | 48,798 | $0.10 | $0.10 | $0.10 |
| 01 Apr 2026 | $0.09 | $0.00 | 0.00% | 49,980 | $0.09 | $0.10 | $0.09 |
| 31 Mar 2026 | $0.09 | $0.00 | 0.00% | 162,959 | $0.09 | $0.09 | $0.09 |
| 30 Mar 2026 | $0.09 | $-0.01 | -9.76% | 104,149 | $0.09 | $0.10 | $0.09 |
| 27 Mar 2026 | $0.10 | $0.00 | 0.00% | 3,989 | $0.10 | $0.10 | $0.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Mar 2026 | Jayne Shaw | Buy | 225,000 | $21,835 |
On-market trade.
|
| 18 Mar 2026 | Jayne Shaw | Buy | 85,000 | $8,477 |
On-market trade.
|
| 16 Mar 2026 | Jayne Shaw | Buy | 300,000 | $29,251 |
On-market trade.
|
| 20 Feb 2026 | Jayne Shaw | Buy | 192,000 | $23,615 |
On-market trade.
|
| 03 Nov 2025 | Jayne Shaw | Buy | 96,722 | $9,189 |
On-market trade.
|
| 02 Sep 2025 | Jayne Shaw | Buy | 306,697 | $19,885 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David George Darling | Non-Executive Director | Mar 2024 |
Mr Darling brings commercial experience from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, he held senior management positions with Fletcher Challenge.
|
| Ms Jayne Andrea Shaw | Executive ChairmanExecutive Director | Feb 2010 |
Ms Shaw has been a member of several private healthcare boards involved with specialist consolidation including cardiology, orthopaedics, and women's health, and continued to work with private equity firms on local and International Healthcare transactions.
|
| Mr Mark Steven McConnell | Non-Executive Director | Feb 2026 |
Mr McConnell is a business developer whose skills cover the areas of business strategy, investor relations, capital raising and innovation. After serving as an officer in the Royal Australian Air Force for almost a decade, Mark moved into the corporate world and for the past 28 years has worked across various executive roles in aviation, technology and investment banking. Mr McConnell has a commitment to community and has served on the boards of numerous charities, not for profit and sporting organisations. He is also a Non-Executive Director of Adveritas Ltd (ASX: AV1).
|
| Dr John Hurrell | Non-Executive Director | Feb 2022 |
Dr Hurrell has developed and commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including life science companies based on university-developed technologies. Other previous roles include Senior Vice President, US R&D Operations for Boehringer Mannheim, now Roche Diagnostics, a remote chronic disease patient management company with a focus on diabetes and kidney disease, President of the Asia/Pacific region and Head of International Sales for PTS Diagnostics, a diabetes and wellness company based in Indiana, USA, and more.
|
| Mr Jonathan Alfred Grey Trollip | Non-Executive Director | Dec 2020 |
Mr Trollip is a non-executive Director with over 30 years of commercial, corporate, governance and legal and transactional expertise. He is the Chair of the Risk Management Committee.
|
| Mr Guy Adrian Robertson | Chief Financial OfficerCompany Secretary |
-
|
|
| Mr Shane Ryan | Chief Executive Officer | Apr 2024 |
-
|
| Shane Ryan | Chief Executive Officer |
-
|
|
| Guy Adrian Robertson | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Capital Property Corporation Pty Ltd <Carrington A/C> | 42,970,028 | 11.74% |
| Mera Vale No 2 Pty Ltd <Mera Vale No 2 A/C> | 25,390,415 | 6.94% |
| Nabelle Pty Ltd <The Shaw Super Fund A/C> | 19,162,405 | 5.24% |
| Ann Marie Phillips | 11,051,179 | 3.02% |
| Australian Philanthropic Services Foundation Pty Ltd <Aps Foundation A/C> | 11,000,000 | 3.01% |
| Ronald Anthony Phillips | 10,912,486 | 2.98% |
| Netwealth Investments Limited <Wrap Services A/C> | 9,769,007 | 2.67% |
| Rapcor Pty Limited <Rapcor Superfund A/C> | 6,973,540 | 1.91% |
| Coolbrun Pty Ltd <The Coolbrun Family A/C> | 6,633,789 | 1.81% |
| Piaster Pty Ltd <Trollip Family S/F A/C> | 6,303,442 | 1.72% |
| Dr Russell Kay Hancock | 5,000,000 | 1.37% |
| Nabelle Pty Ltd <The Shaw Super Fund A/C> i | 4,459,062 | 1.22% |
| Carwoola Pastoral Co Pty Limited | 4,424,895 | 1.21% |
| Innovative Management Pty Ltd <Thn Family Office A/C> | 4,000,000 | 1.09% |
| John Hurrell | 4,000,000 | 1.09% |
| Pandak Pty Ltd | 3,986,096 | 1.09% |
| Angelo Korsanos and Antonia Korsanos <Korsanos Family A/C> | 3,984,050 | 1.09% |
| Vintage Dawn Pty Ltd <Jamie and Caroline Odell S/F> | 3,984,050 | 1.09% |
| Nabelle Pty Ltd <The Shaw Super Fund A/C> ii | 3,852,037 | 1.04% |
| Mr Sean Alexander Kennedy | 3,300,303 | 0.90% |
| HSBC Custody Nominees (Australia) Limited | 3,106,332 | 0.85% |
| Darville Pty Limited | 3,101,660 | 0.85% |
